This invention relates to a recombinant polypeptide encoding the SARS-CoV-2 spike protein candidate vaccine. The invention also relates to vectors comprising nucleic acids encoding the recombinant polypeptide. The invention specifically relates to the recombinant proteins described herein, methods of producing the recombinant proteins and pharmaceutical compositions either comprising the recombinant proteins and/or vectors comprising a nucleic acid encoding the recombinant protein. More specifically, the invention relates to a DNA vaccine, modified vaccinia Ankara virus vaccine and/or a lumpy skin disease virus vaccine encoding the recombinant protein of the invention.